---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-046380"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:54:33.945296+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings subsidiary Cyclo Therapeutics licenses MIT patent for cyclodextrins in ApoE4+ Alzheimer's

## Summary
- Exclusive license covers U.S. Patent No. 12285440 for cyclodextrins in ApoE4-positive Alzheimer's patients.
- ApoE4 variant present in 50-70% of Alzheimer's patients; Trappsol Cyclo targets cholesterol transport in CNS.
- Phase 3 results for Transport NPC program due in calendar Q3 2026, per COO Joshua Fine.
- CEO Howard Jonas calls the license a transformative milestone for the company.

## SEC filing metadata
- accession: 0001213900-26-046380
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390026046380/0001213900-26-046380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390026046380/ea0287258-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-046380
- JSON: https://secwatch.observer/filing/0001213900-26-046380.json
- Plain text: https://secwatch.observer/filing/0001213900-26-046380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.